Achieve Life Sciences Stock (NASDAQ:ACHV)
Previous Close
$4.16
52W Range
$3.03 - $5.98
50D Avg
$4.72
200D Avg
$4.66
Market Cap
$149.25M
Avg Vol (3M)
$107.44K
Beta
1.58
Div Yield
-
ACHV Company Profile
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NXTC | NextCure, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| NLTX | Neurogene Inc. |
| SPRO | Spero Therapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| CHRS | Coherus BioSciences, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| AVRO | AVROBIO, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| GRCL | Gracell Biotechnologies Inc. |
| CNSP | CNS Pharmaceuticals, Inc. |